(The Hill) — Drugmaker AstraZeneca will cap out-of-pocket costs at $35 for all its inhaler products, the company announced Monday. The cap is effective June 1 and will apply to the company’s ...
A small proportion of veterans who went from a metered-dose inhaler to a dry-powder inhaler had to revert to the metered-dose ...
UK-based global pharma company AstraZeneca and US consumer products company Honeywell have announced a partnership to build a new "next generation" inhaler with a propellant that reduces Global ...
President Trump rescinded an executive order that prompted the creation of three Medicare drug-pricing experiments ...
AstraZeneca recently announced the completion of clinical studies for a next-generation propellant (NGP) version of its chronic obstructive pulmonary disease (COPD) inhaler, Breztri. This new ...
AstraZeneca is a leader in cancer treatments with FDA-approved drugs. Read why AZN stock is still a 'Buy' and why the company’s future looks bright.
AstraZeneca’s respiratory and immunology portfolio is driving significant growth, with R&I assets forecasted to account for ...
AstraZeneca faces significant challenges amid Chinese investigation and ongoing investor lawsuit regarding alleged misconduct ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback